Arca
Skip to content

Alagille syndrome

Drug research and approvals for alagille syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 10 studies of alagille syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 3 approved and 2 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 10
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 3
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 10 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Aug 26, 2021An open label study to evaluate the long-term safety and efficacy of odevixibat (a4250) in patients with alagille syndromeODEVIXIBAT (A4250)ALBIREO ABClosed
Dec 22, 2020A phase 3 double-blind, randomized, placebo-controlled study of the safety and efficacy of odevixibat (a4250) in patients with alagille syndrome (assert)ODEVIXIBAT (A4250)ALBIREO ABClosed
Feb 14, 2020A long-term safety study of maralixibat, an apical sodium dependent bile acid transporter inhibitor (asbti), in the treatment of cholestatic liver disease in…MARALIXIBAT (LUM001, SHP625)Mirum PharmaceuticalsClosed
Jun 5, 2014A multicenter extension study to evaluate the long-term safety and durability of the therapeutic effect of lum001, an apical sodium-dependent bile acid…MARALIXIBAT (LUM001)Mirum PharmaceuticalsOngoing
Apr 23, 2014Iconic study long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period of lum001, an apical sodium-dependent bile…MARALIXIBAT (LUM001)LUMENA PHARMACEUTICALS INCClosed
Feb 6, 2014A multicentre extension study to evaluate the long-term safety and durability of the therapeutic effect of lum001, an apical sodium-dependent bile acid…LUM001LUMENA PHARMACEUTICALS INCClosed
Feb 6, 2014A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of lum001, an apical sodium-dependent bile acid transporter inhibitor…LUM001LUMENA PHARMACEUTICALS INCClosed
Feb 6, 2014The evaluation of the intestinal bile acid transport (ibat) inhibitor lum001 in the reduction of pruritus in alagille syndrome, a cholestatic liver diseaseMARALIXIBAT (LUM001)LUMENA PHARMACEUTICALS INCClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Jun 13, 2023Bylvaytreatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS)Ipsen Biopharmaceuticals, Inc.Approved
Mar 13, 2023Livmarlitreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and olderMirum Pharmaceuticals, Inc.Approved
Sep 29, 2021LivmarliTreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and olderMirum Pharmaceuticals, Inc.Approved
Oct 24, 202427mer antisense oligonucleotide with methoxyethyl,…treatment of Alagille syndromeArnatar Therapeutics, Inc.Designated
Sep 3, 2004Buffered Ursodeoxycholic AcidTreatment of pruritus in patients with Alagille SyndromeDigestive Care, Inc.Designated

Medicines Authorised in the EU

Newest first
Sep 19, 2024KayfandaodevixibatIpsen PharmaEMA ↗
Dec 9, 2022Livmarlimaralixibat chloride · orphanMirum Pharmaceuticals International B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.